Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout

Benef Microbes. 2015;6(6):799-806. doi: 10.3920/BM2015.0015. Epub 2015 Aug 31.


Gout is an acute inflammatory disease characterised by the presence of uric acid crystals in the joint. This event promotes neutrophil infiltration and activation that leads to tissue damage. We investigated here whether the oral administration of the probiotic strain Bifidobacterium longum 5(1A) (BL) could ameliorate monosodium urate crystal (MSU)-induced inflammation in a murine model of gout. Mice received oral administration of BL or saline daily for 7 days and then were injected with MSU in the knee cavity. Treatment with BL significantly alleviated the inflammatory parameters, as seen by reduced hypernociception, reduced neutrophil accumulation in the joint and myeloperoxidase activity in periarticular tissue. There was inhibition of the production of CXCL1 and interleukin(IL)-1β in joints. Levels of the anti-inflammatory cytokine IL-10 were significantly higher in the knee tissue of mice treated with than control mice injected with MSU. In conclusion, oral BL treatment reduced the inflammatory response in an experimental murine model of gout, suggesting it may be useful as an adjuvant treatment in patients with gout.

Keywords: Bifidobacterium; gout; inflammation; probiotics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Bifidobacterium*
  • Cytokines / analysis
  • Disease Models, Animal
  • Gout / pathology*
  • Gout / therapy*
  • Gout Suppressants / administration & dosage*
  • Inflammation / pathology*
  • Inflammation / therapy*
  • Mice, Inbred C57BL
  • Probiotics / administration & dosage*
  • Synovial Fluid / chemistry
  • Uric Acid / analysis


  • Cytokines
  • Gout Suppressants
  • Uric Acid